TP53 and B-cell chronic lymphocytic leukemia: Of note, decreased apoptotic priming was evident in RS but not in relapsed/refractory CLL samples (P < 0.001 when comparing relapsed/refractory CLL cases with RS samples), indicating that high-grade transformation and not simply disease relapse or TP53 mutational status (Supplementary Fig. 3) is required to modulate the apoptotic priming.